LitAlert ~~ GeneLit.com

    • Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access.
    • Amendola LM, Shuster E, Leo MC., Dorschner MO, Rolf BA, Shirts BH, Gilmore MJ, Okuyama S, Zepp JM, Kauffman TL, Mittendorf KF, Bellcross C, Jenkins CL, Joseph G, Riddle L, Syngal S, Ukaegbu C, Goddard KAB, Wilfond BS, Jarvik GP; On behalf of theCHARM Study.
    • Genet Med. 2022 Mar 16. doi: 10.1016/j.gim.2022.02.006. Epub ahead of print.
    • A BRCA1 Splice Site Variant Responsible for Familial Ovarian Cancer in a Han-Chinese Family.
    • Hu PZ, Chen XY, Xiong W, Yang ZJ, Li XR, Deng WZ, Gong LN, Deng H, Yuan LM.
    • Curr Med Sci. 2022 Mar 15. doi: 10.1007/s11596-022-2527-2. Epub ahead of print.
    • Case report
    • The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population.
    • Luo Y, Wu H, Huang Q, Rao H, Yu Z, Zhong Z.
    • Int J Gen Med. 2022 Mar 10;15:2773-2786. doi: 10.2147/IJGM.S355755.
    • Identification of the c.829_832delAATA Deletion Variants in the BRCA1 Gene Associated with Hereditary Breast/Ovarian Cancer - Case Report.
    • Ostrowska M, Olszewska-Bozek K, Podlodowska J, Sierocinska-Sawa J, Wojcierowski J.
    • J Genomics. 2022 Feb 14;10:33-38. doi: 10.7150/jgen.68220.